|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | Some private research indicates cell-therapy sponsors aren't happy with outsourcing options. In this part two with a successful investor, we find out how that sentiment might change for the better. |
|
|
FDA’s Updated Guidance On Human Genome Editing: New Implications & Remaining Questions | By Brent Morse and Nate Manley, Dark Horse Consulting | On Jan. 29, 2024, the FDA released the final version of the guidance document on human gene therapy products incorporating genome editing. This article shares what changed between the draft and now final version of the guidance, and what open questions remain for the industry and scientific community to help resolve. |
|
|
|
|
|
Optimization Of Nuclease Digestion Unit Operation In A LVV Process | Poster | By James Xin, Nhi Tran, Chyan-Jang Lee, Briana Orlando, Daniel Kennedy, Miranda Williams, Christine Beaudry, Lorenz Ponce, Chase Waxman, et al., ElevateBio | Discover the statistical analysis results based on several DoE studies for the reduction of hcDNA and pDNA levels in a lentiviral vector (LVV) platform process. |
|
|
|
|
|
|
|
Allegro Ready Filter Sets | Cytiva | Allegro Ready filter sets can be used in wide range of applications, including mAbs, vaccines, plasma, cell, and gene therapies. |
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
Connect With Outsourced Pharma: |
|
|
|